These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma. Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140 [TBL] [Abstract][Full Text] [Related]
9. Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493 [TBL] [Abstract][Full Text] [Related]
10. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients. Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129 [TBL] [Abstract][Full Text] [Related]
11. KIT amplification and gene mutations in acral/mucosal melanoma in Korea. Yun J; Lee J; Jang J; Lee EJ; Jang KT; Kim JH; Kim KM APMIS; 2011 Jun; 119(6):330-5. PubMed ID: 21569090 [TBL] [Abstract][Full Text] [Related]
12. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma. Yaman B; Akalin T; Kandiloğlu G Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015 [TBL] [Abstract][Full Text] [Related]
13. Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667 [No Abstract] [Full Text] [Related]
14. Melanoma hyperpigmentation is strongly associated with KIT alterations. Wu JM; Alvarez H; García P; Rojas PL; Wong G; Maitra A; Antonescu C; Montgomery EA Am J Dermatopathol; 2009 Oct; 31(7):619-25. PubMed ID: 19652585 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathological characteristics and prognosis of amelanotic acral melanoma: A comparative study with pigmented acral melanoma. Gong HZ; Zheng HY; Li J Australas J Dermatol; 2020 Nov; 61(4):358-361. PubMed ID: 32424819 [TBL] [Abstract][Full Text] [Related]
16. Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma. Hou JY; Baptiste C; Hombalegowda RB; Tergas AI; Feldman R; Jones NL; Chatterjee-Paer S; Bus-Kwolfski A; Wright JD; Burke WM Cancer; 2017 Apr; 123(8):1333-1344. PubMed ID: 28026870 [TBL] [Abstract][Full Text] [Related]
17. Amelanotic Acral Melanoma Associated with KIT Mutation and Vitiligo. Kim YJ; Lee JB; Kim SJ; Lee SC; Won YH; Yun SJ Ann Dermatol; 2015 Apr; 27(2):201-5. PubMed ID: 25834362 [TBL] [Abstract][Full Text] [Related]
19. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands. van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725 [TBL] [Abstract][Full Text] [Related]
20. The molecular profile of metastatic melanoma in Australia. Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]